I'm sure data will also be analyzed by AD severity at start, as treating mild patients is expected to be more efficient than treating more advanced ones. Question is do they have enough mild patients in the trial to see a stat-sig effect in this group.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.